ExLibris header image
SFX Logo
Title: A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles
Source:

Journal of Medicinal Chemistry [0022-2623] Guangxin Xia, Wenteng yr:2014


Collapse list of basic services Basic
Full text
Full text available via American Chemical Society Journals
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Hirsch, Fred R. EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients. Link to SFX for this item
2. Roberts, Marisa K. "Investigating extracellular in situ EGFR structure and conformational changes using FRET microscopy." Biochemical Society transactions 40.1 (2012): 189-194. Link to SFX for this item
3. Varkondi, E. "Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor." Journal of receptor and signal transduction research 28.3 (2008): 295-306. Link to SFX for this item
4. Roskoski, R. "The ErbB/HER family of protein-tyrosine kinases and cancer." Pharmacological research 79.C (2013): 34-74. Link to SFX for this item
5. Li, S. "Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening." Bioorganic and medicinal chemistry letters 22.12 (2012): 4004-4009. Link to SFX for this item
6. Paul, Manash K. "Tyrosine kinase–Role and significance in Cancer." International journal of medical sciences 1.2 (2004): 101-115. Link to Full Text for this item Link to SFX for this item
7. Boran, Aislyn D W D. "The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor." Biochemical Society transactions 40.1 (2012): 195-199. Link to SFX for this item
8. Lurje, G. "EGFR Signaling and Drug Discovery." Oncology; Basel 77.6 (2010): 400-410. Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced